Iloperidone, asenapine and lurasidone: a primer on their current status
Authors:
- 31 July 2012
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 13 (13) , 1911-1922
Abstract
Introduction: Three newer atypical antipsychotic drugs were FDA-approved in 2009 and 2010 in the following order: iloperidone, asenapine and lurasidone. The three drugs are indicated for the treatment of acute schizophrenia. Asenapine is also approved for treatment of manic or mixed episodes associated with bipolar I disorder, for the maintenance treatment of schizophrenia and as an adjunctive therapy with lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Areas covered: This review compares and contrasts the current preclinical, clinical, safety and tolerability profiles of the three newer drugs, as reported in published preclinical and clinical studies, product labels, poster presentations and press releases. Expert opinion: Preclinical studies have reported that the three drugs have variable affinities for a wide range of neurotransmitter receptors, and are active in animal models predictive of antipsychotic activity. Asenapine is the first antipsychotic to be administered sublingually, whereas iloperidone requires titration to minimize orthostatic hypotension. Asenapine and lurasidone are associated with dose-related akathisia, whereas iloperidone is not. The three drugs appear to have relatively benign metabolic profiles. The availability of the three novel antipsychotics should provide additional options for improved treatment of schizophrenia and other psychotic disorders.Keywords
This publication has 64 references indexed in Scilit:
- Asenapine Versus Olanzapine in People With Persistent Negative Symptoms of SchizophreniaJournal of Clinical Psychopharmacology, 2012
- Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar DisorderJournal of Clinical Psychopharmacology, 2012
- Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant StrategyNeuropsychopharmacology, 2011
- Asenapine effects in animal models of psychosis and cognitive functionPsychopharmacology, 2009
- 5-HT1A receptor function in major depressive disorderProgress in Neurobiology, 2009
- Safety Profile of IloperidoneJournal of Clinical Psychopharmacology, 2008
- The Burden of Schizophrenia on CaregiversPharmacoEconomics, 2008
- Efficacy and Tolerability of Asenapine in Acute SchizophreniaThe Journal of Clinical Psychiatry, 2007
- Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-VSchizophrenia Bulletin, 2007
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000